Amneal Pharma Stock Rises On FDA Approval For Generic Version Of Abbvie's Eyedrops
(MENAFN- AsiaNet News)
Amneal Pharmaceuticals (AMRX) said on Tuesday that its generic equivalent of AbbVie's (ABBV) eyedrops received approval from the U.S. Food and Drug Administration.
The company's Bimatoprost ophthalmic solution 0.01% is indicated for reducing high eye pressure in patients with open-angle glaucoma or ocular hypertension. It is a generic equivalent of LUMIGAN 0.01%, whose design is a trademark of AbbVie's Allergan.
Shares of the company rose 5% in the pre-market session at the time of writing.
Get updates to this developing story <directly on Stocktwits.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
- Utila Triples Valuation In Six Months As Stablecoin Infrastructure Demand Triggers $22M Extension Round
- Cregis Joins TOKEN2049 Singapore 2025
- Jpmorgan Product Head Joins GSR Trading MD To Build Institutional Staking Markets
- Stratx Launches Compliance-Aware Routing Protocol For Stablecoins, Rwas, And Cross-Border Settlement
- “Farewell To Westphalia” Explores Blockchain As A Model For Post-Nation-State Governance
- DOLLUM Expands Wallet Opportunities, Introducing New Security Features Following The DOL Token Sale
More Story
Comments
No comment